Gold prices bounce off 3-week lows; demand likely longer term
WALTHAM, MA—Khalifa Sammy, the Chief Technology Officer of Vicarious Surgical Inc. (NYSE:RBOT), recently sold 653 shares of the company’s Class A common stock, according to a filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $7.5224, resulting in a total transaction value of $4,912. The stock currently trades at $7.58, within its 52-week range of $4.27 to $19.00, with a market capitalization of approximately $45 million.
The sale was conducted on May 20, 2025, and was executed to cover tax withholding obligations related to the vesting of restricted stock units granted on May 19, 2022. Following this transaction, Sammy holds 35,869 shares directly. According to InvestingPro, while the stock has shown strong returns over the past month, three analysts have recently revised their earnings expectations downward for the upcoming period.
Vicarious Surgical, known for its innovative robotic surgical systems, continues to be a significant player in the medical technology sector. The company maintains a healthy liquidity position with a current ratio of 5.05. Investors and analysts will likely keep a close watch on insider transactions like these, as they can provide insights into the company’s financial strategies and insider sentiment. For deeper insights into RBOT’s valuation and 10+ additional ProTips, access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Vicarious Surgical Inc. reported its financial results for the first quarter of 2025, revealing an adjusted net loss of $15.3 million, or $2.58 per share. The company successfully reduced its operating expenses by 2% compared to the same period in 2024, with research and development expenses decreasing while general and administrative expenses saw a slight increase. Vicarious Surgical is advancing its surgical robotic systems, aiming to become a clinical-stage company by 2025, and has made significant strides in preparing for human clinical trials. The company is also leveraging strategic partnerships, such as the recent collaboration with UMass Memorial Medical (TASE:BLWV) Center, to optimize surgical workflows and enhance system integration. Analysts from BTIG and TD Cowen have shown interest in the company’s cash management and supply chain capabilities, with Vicarious Surgical maintaining a cash balance of $37 million and projecting a full-year cash burn of $50 million. The company continues to focus on securing regulatory approvals and is preparing a technical dossier for submission by mid-2025. As Vicarious Surgical progresses towards its clinical milestones, it remains committed to disciplined capital allocation and strategic financing options.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.